Format

Send to

Choose Destination
Ann Surg Oncol. 2019 Sep 18. doi: 10.1245/s10434-019-07830-w. [Epub ahead of print]

The Landmark Series: MSLT-1, MSLT-2 and DeCOG (Management of Lymph Nodes).

Author information

1
Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA. bellod@mskcc.org.
2
Department of Surgery, Cedars-Sinai Medical Center, Los Angeles, CA, USA.

Abstract

Management of regional lymph nodes in patients with melanoma has evolved significantly in recent years. The value of nodal intervention, long utilized for its perceived therapeutic benefit, has now shifted to that of a critical prognostic procedure used to guide clinical decision making. This review focuses on the three landmark, randomized controlled trials evaluating the role of surgery for regional lymph nodes in melanoma: Multicenter Selective Lymphadenectomy Trial I (MSLT-I), German Dermatologic Cooperative Oncology Group-Selective Lymphadenectomy Trial (DeCOG-SLT), and Multicenter Selective Lymphadenectomy Trial II (MSLT-II).

PMID:
31535299
DOI:
10.1245/s10434-019-07830-w

Supplemental Content

Full text links

Icon for Springer
Loading ...
Support Center